# Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

> **NCT02367040** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 458 (actual)

## Conditions studied

- Lymphoma,Non-Hodgkin

## Interventions

- **DRUG:** Copanlisib (Aliqopa, BAY80-6946)
- **DRUG:** Placebo
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02367040
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-03
- **Primary completion:** 2020-08-31
- **Final completion:** 2024-11-15
- **Target enrollment:** 458 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367040, "Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02367040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*